481 results match your criteria: "TX A.N.; and California Pacific Medical Center[Affiliation]"
Multi-ancestry genome-wide study in >2.5 million individuals reveals heterogeneity in mechanistic pathways of type 2 diabetes and complications.
medRxiv
March 2023
Institute of Translational Genomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Type 2 diabetes (T2D) is a heterogeneous disease that develops through diverse pathophysiological processes. To characterise the genetic contribution to these processes across ancestry groups, we aggregate genome-wide association study (GWAS) data from 2,535,601 individuals (39.7% non-European ancestry), including 428,452 T2D cases.
View Article and Find Full Text PDFExtracorporeal hemoperfusion (EHP) may improve the course and outcomes of patients with septic shock by targeting cytokines or bacterial endotoxins (lipopolysaccharide [LPS]). Here, we present the results of a multicenter randomized controlled trial ( clinicaltrials.gov/ct2/show/NCT04827407 ) to assess the efficiency and safety of Efferon LPS hemoperfusion cartridges engineered for multimodal targeting LPS, host-derived cytokine, and damage-associated molecule pattern molecules.
View Article and Find Full Text PDFAssociation of Brain Age, Lesion Volume, and Functional Outcome in Patients With Stroke.
Neurology
May 2023
From the Laboratory of Neuro Imaging (G.B.), Imaging Genetics Center (N.J., P.M.T.), and Department of Neurology (N. Sanossian, C.J.W.), Mark and Mary Stevens Neuroimaging and Informatics Institute (S.-L.L., J.H.K., H.K., G.P.), Keck School of Medicine, University of Southern California, Los Angeles; Chan Division of Occupational Science and Occupational Therapy (S.-L.L., B.P.L., M.R.D., J.N.J., Z.W., A.A., A.H., J.A.H., J.L.M.), Division of Biokinesiology and Physical Therapy (N. Schweighofer, C.J.W., S.-L.L.), and Herman Ostrow School of Dentistry, University of Southern California, Los Angeles; Centre for Medical Image Computing (J.H.C.), Department of Computer Science, Dementia Research Centre (J.H.C.), Queen Square Institute of Neurology, University College London, United Kingdom; Brain Mapping Center (A.Z.-P.), Department of Neurology, Geffen School of Medicine, University of California, Los Angeles; Centre for Youth Mental Health (L.K.M.H., L.S.) and Melbourne School of Psychological Sciences (N.E.-B.), University of Melbourne, Parkville, Victoria, Australia; Institute for Translational Psychiatry (T.H.), University of Münster, Germany; Department of Physical Therapy and Djavad Mowafaghian Centre for Brain Health (L.A.B.), University of British Columbia, Vancouver, Canada; The Florey Institute of Neuroscience and Mental Health (A.B., K.H., M.S.K.); Eastern Cognitive Disorders Clinic (A.B.); Royal Melbourne Hospital (A.B.), Victoria, Australia; Department of Neurology (C.M.B.) and Facility for Education and Research in Neuroscience (K.P.R.), Emory University, Atlanta, GA; Centre for Brain Research and Department of Exercise Sciences (W.D.B.), University of Auckland, New Zealand; Department of Health Sciences (J.M.C.), University of North Carolina at Chapel Hill; Department of Basic and Clinical Sciences (C.C.C.), Center for Neuroscience and Integrative Brain Research (CENIBRE) (C.C.C.), University of Nicosia Medical School, Cyprus; Laboratory of Neuropsychiatry (V.C., F.P.), IRCCS Santa Lucia Foundation, Rome, Italy; Hospital das Clínicas (A.B.C.), São Paulo University; Hospital Israelita Albert Einstein (A.B.C.), São Paulo, Brazil; Department of Psychiatry and Clinical Psychobiology (R.D.-A.), Universitat de Barcelona, Spain; Center for Neurotechnology and Neurorecovery (J.A.D., D.J.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Functional Imaging Unit (M.D.), Diagnostic and Neuroradiology and Functional Imaging Unit (M.L.), Diagnostic Radiology and Neuroradiology, Universitymedicine Greifswald, Germany; Departments of Neurology (A.N.D.) and Physical Medicine & Rehabilitation (K.A.W.), Dell Medical School at The University of Texas Austin; Department of Neurology (W.F.), Duke University School of Medicine, Durham, NC; Clinical Language and Cognition (CLC) Lab (F.G.), Department of Brain Sciences, Imperial College London, United Kingdom; Department of Health Sciences & Research (C.M.G., S.A.K.), Medical University of South Carolina, Charleston; Cancer Biology (C.A.H.), Wake Forest School of Medicine, Winston Salem, NC; Innovation, Implementation and Clinical Translation (IIMPACT) in Health (B.H.), Allied Health and Human Performance, University of South Australia, Adelaide; Ralph H. Johnson VA Medical Center (S.A.K., N.J.S.), Charleston, SC; Department of Radiology (A.K., E.R.O.), Weill Cornell Medicine, New York, NY; Department of Radiology (J.L., C.Y.), Tianjin Medical University General Hospital, China; Hurvitz Brain Sciences Program (B.J.M.), Centre for Brain Resilience & Recovery and Canadian Partnership for Stroke Recovery (A.D.R.), Sunnybrook Research Institute, Toronto, Ontario, Canada; Computational Radiology Artificial Intelligence Unit (B.J.M.) and Norwegian Centre for Mental Disorders Research (NORMENT) (L.T.W.), Department of Mental Health and Addiction, Oslo University Hospital, Norway; Department of Clinical Psychology and Psychobiology (M.M.), and Institut de Neurociències (M.M.), University of Barcelona; Institut de Recerca Pediàtrica (M.M.), Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain; Jefferson Integrated MRI Center (F.B.M.), Department of Radiology, Thomas Jefferson University, Philadelphia, PA; Cedars-Sinai (P.R.), Los Angeles, CA; California Rehabilitation Institute (P.R., S.C.C.), Los Angeles; Department of Kinesiology and Health Sciences (A.D.R.), University of Waterloo, Ontario, Canada; Department of Neurology (H.M.S., M.T.), NYU Langone, New York; Department of Rehabilitation Sciences (N.J.S.), and Department of Health Sciences and Research (N.J.S.), Medical University of South Carolina, Charleston; Department of Psychiatry and Neurosciences (S.R.S.), Clinical Neurotechnology Laboratory, Charité-Universitätsmedizin Berlin, Germany; Laboratory of Neuropsychiatry (G.S.), IRCCS Santa Lucia Foundation, Rome, Italy; Division of Neuropsychiatry (G.S.), Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX; Department of Medicine (C.M.S.), University of Auckland, New Zealand; Department of Psychiatry (W.K.T.), Faculty of Medicine, The Chinese University of Hong Kong; Department of Physical Therapy and Neuroscience (G.T.T.), University of the Sciences, Philadelphia, PA; Department of Clinical and Behavioral Neurology (D.V.), IRCCS Santa Lucia Foundation, Rome, Italy; UCL Queen Square Institute of Neurology (N.S.W.), London, United Kingdom; Department of Psychology (L.T.W.), University of Oslo, Norway; Department of Neurology & RNEL (G.F.W.), University of Pittsburgh; GRECC/HERL (G.F.W.), VA Pittsburgh Healthcare System, PA; Department of Rehabilitation Medicine Division of Physical Therapy (M.R.B., S.L.W.), Department of Rehabilitation Medicine, Division of Geriatric Medicine (S.L.W.), Department of Medicine, and Department of Cell Biology (S.L.W.), Emory University School of Medicine; Center for Visual and Neurocognitive Rehabilitation (S.L.W.), Atlanta VA Health Care System, GA; and Department of Neurology (S.C.C.), University of California, Los Angeles. Giuseppe Barisano is currently at the department of Neurosurgery, Stanford Medicine, Stanford University, CA; Kathryn Hayward is currently at the departments of Physiotherapy and Medicine (RMH), University of Melbourne, Parkville, Victoria, Australia; and Gregory T. Thielman is currently at Physical Therapy and Neuroscience, School of Health Professions, Saint Joseph's University, Philadelphia, PA.
Background And Objectives: Functional outcomes after stroke are strongly related to focal injury measures. However, the role of global brain health is less clear. In this study, we examined the impact of brain age, a measure of neurobiological aging derived from whole-brain structural neuroimaging, on poststroke outcomes, with a focus on sensorimotor performance.
View Article and Find Full Text PDFBest ablation strategy in patients with premature ventricular contractions with multiple morphology: a single-centre experience.
Europace
May 2023
Department of Electrophysiology, Texas Cardiac Arrhythmia Institute, St. David's Medical Center, TCAI: 1015 east 32nd street, suite 408, Austin, TX-78705, USA.
Aims: This study aimed to examine the clinical benefits of targeted ablation of all Premature ventricular complex (PVC) morphologies vs. predominant PVC only.
Methods And Results: A total of 171 consecutive patients with reduced left ventricular ejection fraction (LVEF) and ≥2 PVC morphology with high burden (>10%/day) undergoing their first ablation procedure were included in the analysis.
Oxoglutarate dehydrogenase complex controls glutamate-mediated neuronal death.
Redox Biol
June 2023
Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA, Vienna, Austria; Austrian Cluster for Tissue Regeneration, Vienna, Austria. Electronic address:
Article Synopsis
- Brain injury causes neuroinflammation, high extracellular glutamate levels, and mitochondrial dysfunction, all contributing to neuronal death.
- The study analyzed patients with aneurysmal subarachnoid hemorrhage and conducted in vitro experiments to investigate the impact of these mechanisms on neuron health.
- Results indicate that the inhibition of the 2-oxoglutarate dehydrogenase complex by nitric oxide leads to increased extracellular glutamate and subsequent neuronal death, while thiamine can help reverse this toxicity.
Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts.
Nat Commun
March 2023
Division of Pulmonary & Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Pulmonary fibrosis (PF) is characterized by profound scarring and poor survival. We investigated the association of leukocyte telomere length (LTL) with chronological age and mortality across racially diverse PF cohorts. LTL measurements among participants with PF stratified by race/ethnicity were assessed in relation to age and all-cause mortality, and compared to controls.
View Article and Find Full Text PDFAssociation of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts.
Neurology
May 2023
From the Department of Biostatistics (Y.Z., X.L., A.P., A.S.B., C.L.), School of Public Health, Boston University, MA; Cardiovascular Health Research Unit (K.L.W., J.C.B.), Department of Medicine, University of Washington, Seattle; Brigham and Women's Hospital (N.K., T.S.), Boston, MA; The Institute for Translational Genomics and Population Sciences (X.G., J.I.R.), Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance; Department of Psychiatry and Behavioral Sciences (A.L.R., D.C.G.), Boston Children's Hospital, MA; Department of Psychiatry (A.L.R., D.C.G.), Harvard Medical School, Boston Children's Hospital, MA; Department of Epidemiology (W.Z., S.M.R., S.L.R.K., J.A.S.), School of Public Health, University of Michigan, Ann Arbor; GeneSTAR Research Program (L.R.Y.), Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; School of Medicine (J.S.A.P.), Universidad de Los Andes, Bogotá, Colombia; Harvard Medical School (T.S.), Boston, MA; McKusick-Nathans Institute (D.E.A.), Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Epidemiology (T.R.A.), University of Washington, Seattle; Department of Neurology (A.S.B.), School of Medicine, Boston University, MA; Framingham Heart Study (A.S.B., D.L., S.S., V.R., C.L., C.L.S.), Framingham, MA; Department of Human Genetics and South Texas Diabetes and Obesity Institute (J. Blangero, J.E.C.), University of Texas Rio Grande, Brownsville; Human Genetics Center (E.B., J. Bressler), School of Public Health, The University of Texas Health Science Center at Houston; Human Genome Sequencing Center (E.B.), Baylor College of Medicine, Houston, TX; Department of Preventive Medicine (L.H.), Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Internal Medicine (T.M.H.), Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC; National Institute on Aging (L.J.L.), and Population Sciences Branch National Heart, Lung, and Blood Institute (D.L.), NIH, Bethesda, MD; Memory Impairment and Neurodegenerative Dementia (MIND) Center (T.H.M.), School of Medicine, University of Mississippi Medical Center, Jackson; Center for Biomedical Image Computing and Analytics (I.M.N.), Department of Radiology, University of Pennsylvania, Philadelphia; Center for Public Health Genomics (S.S.R.), University of Virginia School of Medicine, Charlottesville; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (S.S., C.L.S.), University of Texas Health Science Center at San Antonio; Institute of Gerontology & Department of Healthcare Sciences (W.T.), Wayne State University, Detroit, MI; Department of Neurosciences (K.A.G.) and Shiley-Marcos Alzheimer's Disease Center (H.M.G.), University of California, San Diego, La Jolla; Department of Medicine (V.R.), School of Medicine, and Department of Epidemiology, Boston University, MA; University of California, San Francisco (K.Y.); Department of Neurology (P.A.N.), Johns Hopkins University School of Medicine, Baltimore, MD; Cardiovascular Health Research Unit (B.M.P.), Departments of Medicine, Epidemiology, and Health Systems and Population Health, University of Washington, Seattle; Department of Neurology (C.S.D.), UC Davis, CA; Institute of Molecular Medicine (M.F.), McGovern Medical School; and Human Genetics Center (M.F.), School of Public Health, University of Texas Health Science Center at Houston; and Cardiovascular Health Research Unit and Department of Epidemiology (S.R.H.), and Departments of Family Medicine, Epidemiology, and Global Health (A.L.F.), University of Washington, Seattle.
Article Synopsis
- Previous research indicates a link between lower mitochondrial DNA (mtDNA) copy number and neurodegenerative diseases, prompting investigation into the relationship between mtDNA CN in blood and Alzheimer disease endophenotypes.
- The study involved dementia-free individuals from various community cohorts, measuring mtDNA CN and analyzing its association with cognitive function and brain MRI markers over specified timeframes.
- Findings showed that higher mtDNA CN correlates with better cognitive performance, independent of several confounding factors, with consistent results observed in both cross-sectional and prospective analyses, although the latter showed a weaker association.
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer.
NPJ Precis Oncol
March 2023
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Toll-like receptors (TLRs), which serve as a bridge between innate and adaptive immunity, may be viable treatment targets. TLRs are the first line of defense against microbes and activate signaling cascades that induce immune and inflammatory responses. Patients with "hot" versus "cold" tumors may respond more favorably to immune checkpoint inhibition, and through their downstream effects, TLR agonists have the potential to convert "cold tumors" into "hot tumors" making TLRs in combination with immune checkpoint inhibitors, potential targets for cancer therapies.
View Article and Find Full Text PDFReal-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era.
Eur Urol Open Sci
March 2023
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on real-world usage and outcomes are limited.
Objective: To examine real-world treatment patterns and clinical outcomes for mRCC.
The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson's disease data.
NPJ Parkinsons Dis
March 2023
Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Article Synopsis
- * A virtual 3-day hackathon brought together 49 early-career scientists from 12 countries, focusing on building tools and pipelines specifically for PD research, with each team working on one of nine distinct projects.
- * The hackathon not only generated resources to enhance research but also provided training and networking opportunities, ultimately fostering creative problem-solving and collaboration essential for emerging researchers in data science.
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.
Stroke
March 2023
Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston University School of Medicine, MA (E.J.B.).
Article Synopsis
- Atrial fibrillation (AF) is a major contributor to ischemic stroke, which greatly impacts health and mortality rates, especially as the aging population grows.
- There are various stroke prevention methods available, yet significant questions persist regarding the best strategies for both broader populations and individual patients in managing AF.
- The National Heart, Lung, and Blood Institute workshop highlighted research areas for improvement, including risk assessment tools, challenges related to oral anticoagulants, and the effectiveness of different left atrial appendage closure techniques in stroke prevention for AF patients.
Diazotrophy modulates cyanobacteria stoichiometry through functional traits that determine bloom magnitude and toxin production.
Limnol Oceanogr
February 2023
Center for Reservoir and Aquatic System Research, Baylor University, Waco TX, 76798, USA.
Article Synopsis
- Harmful cyanobacterial blooms are increasingly threatening water quality, prompting a study on the interactions between nitrogen-fixation and toxin production in cyanobacteria.
- A gradient of nitrogen to phosphorus resources was tested, revealing that low nitrogen to phosphorus (N:P) cultures can match the biomass of high N:P cultures without a tradeoff in nitrogen fixation.
- The results suggest two functional groups among nitrogen-fixing cyanobacteria—N-storage-strategists and growth-strategists—that influence bloom size and toxin production in environmental settings.
Effects of protein-coding variants on blood metabolite measurements and clinical biomarkers in the UK Biobank.
Am J Hum Genet
March 2023
Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Department of Medicine, University of Melbourne, Austin Health, Melbourne, VIC, Australia. Electronic address:
Genome-wide association studies (GWASs) have established the contribution of common and low-frequency variants to metabolic blood measurements in the UK Biobank (UKB). To complement existing GWAS findings, we assessed the contribution of rare protein-coding variants in relation to 355 metabolic blood measurements-including 325 predominantly lipid-related nuclear magnetic resonance (NMR)-derived blood metabolite measurements (Nightingale Health Plc) and 30 clinical blood biomarkers-using 412,393 exome sequences from four genetically diverse ancestries in the UKB. Gene-level collapsing analyses were conducted to evaluate a diverse range of rare-variant architectures for the metabolic blood measurements.
View Article and Find Full Text PDFGenome-Wide Analysis of Structural Variants in Parkinson Disease.
Ann Neurol
May 2023
Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.
Article Synopsis
- The study aimed to identify genetic risk factors for Parkinson disease (PD) by focusing on structural variants (SVs) rather than just single nucleotide variants, which only cover a small part of genetic variation.
- Researchers conducted a large-scale genome-wide association study using data from 7,772 individuals and discovered SVs linked to PD risk in a sample of 2,585 cases and 2,779 controls.
- They validated three novel SVs associated with PD, including a significant deletion within the gene LRRN4, marking this research as the most thorough analysis of SVs' role in PD risk to date.
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
J Immunother Cancer
January 2023
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Background: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.
Methods: Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab).
Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis.
Circulation
January 2023
Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA (D.A.G., J.E.F.).
Background: Taking fewer than the widely promoted "10 000 steps per day" has recently been associated with lower risk of all-cause mortality. The relationship of steps and cardiovascular disease (CVD) risk remains poorly described. A meta-analysis examining the dose-response relationship between steps per day and CVD can help inform clinical and public health guidelines.
View Article and Find Full Text PDFReduced brain activity during a working memory task in middle-aged apolipoprotein E ε4 carriers with overweight/obesity.
Front Hum Neurosci
November 2022
Department of Psychology, University of Pittsburgh, Pittsburgh, PA, United States.
Objective: The apolipoprotein E ε4 (APOE ε4) allele and midlife obesity are independent risk factors for Alzheimer's disease (AD). Both of these risk factors are also associated with differences in brain activation, as measured by blood oxygenation level-dependent (BOLD) responses, in the absence of detectable cognitive deficits. Although the presence of these risk factors may influence brain activity during working memory tasks, no study to date has examined whether the presence of the ε4 allele explains variation in working memory brain activity while matching for levels of overweight/obesity.
View Article and Find Full Text PDFRad regulation of Ca1.2 channels controls cardiac fight-or-flight response.
Nat Cardiovasc Res
November 2022
Division of Cardiology, Department of Medicine, Columbia University, Vagelos College of Physicians and Surgeons, New York, NY, USA.
Article Synopsis
- The study investigates the heart's contractile reserve and how it is affected by β-adrenergic signaling, which traditionally increases heart rate and contractility during stress.
- Researchers find that specific sites on the protein Rad, when modified by a process called phosphorylation, are essential for controlling calcium flow into heart cells (cardiomyocytes), impacting heart performance.
- Mutations in Rad lead to significant decreases in heart function under stress and regular conditions, but introducing modified calcium-channel proteins can restore heart function, indicating potential for new heart treatments.
Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.
Blood
February 2023
Department of Pediatrics, Center for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, TX.
T cells expressing chimeric antigen receptors (CARs) have achieved major clinical success in patients with hematologic malignancies. However, these treatments remain largely ineffective for solid cancers and require significant time and resources to be manufactured in an autologous setting. Developing alternative immune effector cells as cancer immunotherapy agents that can be employed in allogeneic settings is crucial for the advancement of cell therapy.
View Article and Find Full Text PDFMolecular differences between younger versus older ER-positive and HER2-negative breast cancers.
NPJ Breast Cancer
November 2022
Breast Medical Oncology, School of Medicine, Yale University, New Haven, CT, USA.
The RxPONDER and TAILORx trials demonstrated benefit from adjuvant chemotherapy in patients age ≤ 50 with node-positive breast cancer and Recurrence Score (RS) 0-26, and in node-negative disease with RS 16-25, respectively, but no benefit in older women with the same clinical features. We analyzed transcriptomic and genomic data of ER+/HER2- breast cancers with in silico RS < 26 from TCGA (n = 530), two microarray cohorts (A: n = 865; B: n = 609), the METABRIC (n = 867), and the SCAN-B (n = 1636) datasets. There was no difference in proliferation-related gene expression between age groups.
View Article and Find Full Text PDFHepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
J Hepatol
March 2023
ENYO Pharma SA, Lyon, France. Electronic address:
Background & Aims: The LIVIFY trial investigated the safety, tolerability, and efficacy of vonafexor, a second-generation, non-bile acid farnesoid X receptor agonist in patients with suspected fibrotic non-alcoholic steatohepatitis (NASH).
Methods: This double-blind phase IIa study was conducted in two parts. Patients were randomised (1:1:1:1) to receive placebo, vonafexor 100 mg twice daily (VONA-100BID), vonafexor 200 mg once daily (VONA-200QD), or 400 mg vonafexor QD (VONA-400QD) in Part A (safety run-in, pharmacokinetics/pharmacodynamics) or placebo, vonafexor 100 mg QD (VONA-100QD), or VONA-200QD (1:1:1) in Part B.
Morphometric imaging biomarker identifies Alzheimer's disease even among mixed dementia patients.
Sci Rep
November 2022
Synaps Dx, 12358 Parklawn Drive, Rockville, MD, 20852, USA.
A definitive diagnosis of Alzheimer's disease (AD), even in the presence of co-morbid neuropathology (occurring in > 50% of AD cases), is a significant unmet medical need that has obstructed the discovery of effective AD therapeutics. An AD-biomarker, the Morphometric Imaging (MI) assay on cultured skin fibroblasts, was used in a double-blind, allcomers (ages 55-90) trial of 3 patient cohorts: AD dementia patients, N = 25, all autopsy confirmed, non-AD dementia patients, N = 21-all autopsy or genetically confirmed; and non-demented control (AHC) patients N = 27. Fibroblasts cells isolated from 3-mm skin punch biopsies were cultured on a 3-D Matrigel matrix with movement dynamics quantified by image analysis.
View Article and Find Full Text PDFChallenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
NPJ Precis Oncol
October 2022
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (ClinicalTrials.gov: NCT02152254). Patients with metastatic cancer underwent tumor profiling and were randomized between the two arms when eligibility criteria were met (Part A).
View Article and Find Full Text PDFFormation of Lutein, β-Carotene and Astaxanthin in a sp. Isolate.
Molecules
October 2022
Center for Applied Energy Research, University of Kentucky, Lexington, KY 40511, USA.
In this study, the effect of media composition, N/P ratio and cultivation strategy on the formation of carotenoids in a sp. isolate was investigated. A two-stage process utilizing different media in the vegetative stage, with subsequent re-suspension in medium without nitrate, was employed to enhance the formation of carotenoids.
View Article and Find Full Text PDFNeoadjuvant relatlimab and nivolumab in resectable melanoma.
Nature
November 2022
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma. We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV melanoma (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg and relatlimab 160 mg intravenously every 4 weeks) followed by surgery, and then ten doses of adjuvant combination therapy.
View Article and Find Full Text PDF